293 results about "OPHTHALMOLOGICALS" patented technology

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

This invention discloses an ophthalmic disease diagnostic system based on optical coherence tomography (OCT), comprising: an image data acquisition module for acquiring OCT image data; a feature extraction and similarity calculation module for extracting OCT image feature representations and layered structural features of the macular region, calculating macular structural similarity information between different OCT image data, and constructing a structural similarity alignment matrix reflecting the structural similarity among all OCT images; simultaneously constructing an association matrix representing the correspondence between OCT images and disease categories; and a model training module that introduces the structural similarity alignment matrix and association matrix as joint supervision signals into the objective function, adaptively learning to obtain an ophthalmic disease diagnostic model; the ophthalmic disease diagnostic model outputs a classification diagnostic result representing the probability that the input OCT image data belongs to various ophthalmic diseases. This invention achieves automatic identification and classification of ophthalmic diseases, with high diagnostic accuracy and good robustness.

A method for stabilizing a composition for ophthalmic use containing sepetaprost is disclosed. More specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of preservative effectiveness of the composition for ophthalmic use are disclosed. The composition for ophthalmic use contains sepetaprost at a concentration of 0.0001 to 0.003% (w / v) and has a pH within a range from 5 to 8.

The application provides an ophthalmic image diagnosis method and system based on multi-modal imaging cooperation, and relates to the technical field of medical image diagnosis. First, the OCT, fundus camera and ultrasonic original image data of an ophthalmic examination object are acquired, and multi-modal dynamic correlation mapping results are obtained through dynamic correlation and trend correlation processing. Cross-modal lesion feature progressive mining and interactive verification are performed to obtain a cross-modal lesion correlation feature set. Multi-modal cooperative diagnosis reasoning and weight feedback optimization are used to generate an ophthalmic disease reasoning result containing disease types, lesion dynamic distribution and reasoning confidence. Finally, an ophthalmic diagnosis report with dynamic labeling and confidence explanation is generated. The application comprehensively utilizes the advantages of various image technologies to improve the accuracy of ophthalmic image diagnosis.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The utility model relates to ophthalmic treatment equipment technical field discloses an electrode treatment device, including built -in module and external wearing device, built -in module lower end fixed mounting has silica gel pad, built -in module inside fixed mounting has flexible circuit board, and flexible circuit board one end extends to built -in module outside and fixed mounting has electrode module, external wearing device one side fixed mounting has image acquisition module, external wearing device other side fixed mounting has mounting rod, and mounting rod one end fixed mounting has signal transmission module. When installing the electrode module in the retinal area of patient eyeball through the fixing base of outside, can make the electrode module through the internal slot can carry out displacement adjustment in flexible circuit board one end, thereby being convenient for electrode module can adjust to the appropriate position in installation, thereby preventing the operation from being unable to carry out because of the adjustment electrode module leads to flexible circuit board and cannot be pasted with the outside of eyeball and causes.

The disclosure provides a method for additively manufacturing an ophthalmic device delimited by a targeted curved geometrical envelope, thanks to at least one inkjet print head having at least one nozzle, the method comprising inkjet printing a first layer, the first layer being divided into several first sub-layers, and inkjet printing a second layer above the first layer, the second layer being divided into several second sub-layers, wherein a first one of the first sub-layers is disposed and others of the first sub-layers are disposed on and after the first one of the first sub-layers and are each offset from the first sub-layer immediately below by a first determined shifting distance in a first direction inside the targeted curved geometrical envelope, and wherein a first one of the second sub-layers is disposed on the first layer and is offset from the first one of the first sub-layers by a second determined shifting distance lower than the first determined shifting distance and in the first direction inside the targeted curved geometrical envelope; whereby the first one of the second sub-layers at least partially covers at least one of the others of the first sub-layers.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

1. Name of the product in this design: Ophthalmic Examination Device. 2. Purpose of this design: For use in ophthalmic examination devices. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. Design 1 is designated as the basic design.

An ophthalmic device including: a body having: a posterior surface which is adjacent to an eye surface when the ophthalmic device is worn; an anterior surface defining a height of the body above the eye surface; a retention portion, configured to reside between an eyelid and the eye surface, the retention portion bordered by a portion of the anterior surface, and having a height difference of at least 1 mm over at most a 1 mm distance.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

The present invention relates to an apparatus (110) and a method (210) configured to determine a choroidal topography (218) on a region (114, 114') of the retina (116) of a human eye (117), and to the use of the apparatus (110) for determining the effect of at least one ophthalmic lens design on the choroidal topography (218). In this document, the device (110) includes: - at least two separate displays (122, 122'), each configured to provide retinal stimulation (112, 112'), thereby providing two independent retinal stimuli (112, 112'); - at least two optical transmission elements, including a first optical transmission element and a second optical transmission element, each configured to project at least one of the retinal stimulation (112, 112') or a phase map onto a region of the retina of a human eye, wherein the phase map includes a modified retinal stimulation; - a measuring device (142) for capturing a human eye by using reflected light received from a region (114, 114') on the retina (116) of the human eye (117). (117) Choroidal topography (218) on region (114, 114') of retina (116); - Optical filter (152) configured to separate reflected light received from region (114, 114') of retina (116) of human eye (117) from phase map of region (114, 114') of retina (116) of human eye (117), wherein the second optical transmission element is further configured to simultaneously project each of the at least two separate phase maps at different retinal eccentricities onto each of at least two separate regions (134, 134') of retina (116) of human eye (117), wherein these separate regions (134, 134') include peripheral region and foveal region of retina (116) of human eye (117).

The utility model relates to medical instrument technical field, concretely relates to an ophthalmic ultrasonic examination external guiding fixation lamp, including mobile base, the mobile base is installed with the adjusting support, the adjusting support upper end is installed with the universal pipe, the universal pipe end is installed with the mounting seat, the mounting seat is installed with the lamp body, the mounting seat one side installs the switch, controls the lamp body through the switch, the one side of mobile base is provided with foot switch, adjusts the lamp body brightness through foot switch, be provided with the support mechanism between adjusting support and universal pipe, support the universal pipe through the support mechanism, through the mobile base to carry out the installation of equipment, the overall movement of equipment is convenient, realizes the adjustment of height and direction, angle through adjusting support and universal pipe, greatly improved the application scope, the support mechanism supports the universal pipe, improves the stability of universal pipe and lamp body, improved the use effect.

There are provided an ophthalmic device capable of examining on a subject eye by an examination head without bringing the examination head closer to a nose of a subject and a method for operating the ophthalmic device. The ophthalmic device includes a displacement mechanism (an XZ movement mechanism (16), a Y movement mechanism (18), a swing rotation mechanism (20), and a tilt rotation mechanism (80)) configured to displace an examination head (66) with respect to a subject eye (E), a nose photographing controlling unit (41) configured to cause at least two cameras (34a) to photograph a nose of a subject from a plurality of directions different from each other, a nose position detecting unit (42) configured to detect a position of the nose (N) based on respective photographed images of the nose (N) from the cameras (34a), a tilting angle determining unit (43) configured to determine a tilting angle (θ) of an axis (TA) of tilt with respect to a reference axis (VA) based on a result of detection by the nose position detecting unit (42), and a drive controlling unit (46) configured to drive the displacement mechanism to displace the examination head (22) to an examination position for the subject eye (E) along the axis (TA) of tilt with the tilting angle (θ) determined by the tilting angle determining unit (43).

A system and method for fabricating prescription lenses for smart glasses. Frames for smart glasses are selected and worn by a user. The electronics in the smart glasses are linked to a computer. The inclinometer within the smart glasses provides pantoscopic tilt angle data that indicates a combined angle of the frames and the head of the user. Data can be collected and processed as the user moves through various scenarios. The original lens prescription is altered to compensate for the pantoscopic tilt angle data, therein obtaining an altered prescription. The prescription lenses are formed using the altered prescription. In addition, the user can be imaged while wearing the frames. The images can be used to obtain ophthalmic measurements needed to properly fit the smart glasses with the prescription lenses. The imaging can be obtained using the camera within the smart glasses, by imaging in a mirror.

The application discloses a tri-substituted tetrahydroisoquinoline amide derivative with a novel structure or a pharmaceutically acceptable salt thereof, which is a compound shown in formula I. The compound has a strong inhibiting capacity on immune cell migration, the compound itself has high permeability and good water solubility, and can be used as an immune cell migration inhibitor and used for developing a medicine for treating ophthalmic diseases such as dry eye.

This invention discloses an alkaloid compound and its uses. Specifically, the invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I), and also to pharmaceutical compositions comprising said compounds and their uses. In particular, this alkaloid compound has a significant inhibitory effect on angiogenesis and can be used as a medicament for the prevention or treatment of tumors, inflammation, ophthalmic diseases, abnormal fibrosis or scar formation, cardiovascular and cerebrovascular diseases, nervous system diseases, infectious diseases, metabolic diseases, and diseases related to abnormal angiogenesis in mammals.

The invention relates to an ophthalmic article (1), in particular for sunglasses, comprising at least one substrate (9) and a photochromic filter compound (15), the ophthalmic article (1) having a first transmission spectrum in an activated state of the photochromic filter compound (15) and a second transmission spectrum in a deactivated state of the photochromic filter compound, such that: ⋅—the first and the second transmission spectra at wavelengths lower than 380 nm is lower than 1%, ⋅—the first and the second transmission spectra have a relative first maximum between 460 nm and 510 nm, ⋅—the first and the second transmission spectrum have a relative first minimum between 560 nm and 610 nm, and where ⋅—Tvactivated is the luminous transmittance according to ISO_13666 in the activated state of the photochromic filter compound. ⋅—Tvdeactivated is the luminous transmittance according to ISO_13666 in the deactivated state of the photochromic filter compound. ⋅The lens has a reduced transmission in the blue between 400 and 450 nm and a reduced transmission around 585 nm. The lens provides a good contrast and reduces glare.TvdeactivatedTvactivated>2.5TvactivatedTνdeactivated

The utility model relates to medical mask technical field, concretely relates to a breathing mask for ophthalmic operation, including mask body, and setting in the oxygen pipe joint of mask body middle part, the upside of mask body is provided with nose bridge buckling part, the first pipe joint is passed through and is provided with in the root of nose bridge buckling part, the right side below of mask body is provided with second pipe joint, is provided with carbon dioxide collection pipe interface on the second pipe joint, the second pipe joint with carbon dioxide through pipe is set up between the outside end of first pipe joint and is communicated, the inside end of first pipe joint is provided with transnasal collection pipe, solve the breathing mask for ophthalmic operation in the prior art for the poor fit effect of patient's nose, easy to influence medical staff's operation, possibly exist the risk of being infected, also do not have the function of exhaling carbon dioxide collection, the function is relatively single, can not satisfy the problem of clinical use requirement.

This invention relates to an ophthalmic lens and its manufacturing process. The ophthalmic lens includes a lens body, which comprises a central region and an auxiliary region surrounding the central region. The auxiliary region contains a plurality of scattering clusters formed by translational shifts according to a preset period. Each scattering cluster is composed of multiple microstructures arranged according to a spatial lattice configuration. This invention, by first combining multiple microstructures into scattering clusters and then using these clusters to fill the auxiliary region, can, on the one hand, enhance the scattering of incident light in other directions, reducing the angular resolution of the luminescent object; on the other hand, it can ensure the uniformity of the entire scattering cluster by utilizing multiple microstructures arranged according to a spatial lattice configuration, further providing a basis for the optimization of myopia glasses.

This utility model relates to an ophthalmic puncture knife cannula, comprising: a cannula body, the cannula body including a capillary tube and a cannula tailstock formed at and communicating with the end of the capillary tube, the cannula tailstock including at least a tailstock body formed at the end of the capillary tube, a through cavity formed in the tailstock body and communicating with the capillary tube, and a limiting groove formed on the inner wall of the tailstock body and cooperating with the through cavity; and a self-closing cap, the self-closing cap including an insert sleeve disposed in the through cavity, a snap-fit ​​sleeve formed at the end of the insert sleeve and cooperating with the limiting groove, and a thin film formed in the insert sleeve or the snap-fit ​​sleeve. This design prevents the self-closing cap from separating from the cannula body during cleaning and sterilization, thus avoiding the self-closing cap falling off during cleaning.

An ophthalmic lens which may be a contact lens (1, Fig 1A) with an optic zone comprising a distance corrective central region (5, Fig 1A) with on-axis curvature (19, Fig 2A) and a first annular region

An ophthalmic instrument is equipped with LEDs (6). In addition to the LEDs (6), the instrument has a voltage source (B), an inductor (L), and a capacitor (C). The method for operating the instrument comprises at least one charging sequence (Z1) and one illumination sequence (Z2). The charging sequence includes at least a first and at least a second phase (P1, P2). In the first phase (P1), the voltage source (B) and the inductor (L) are connected in series. In the second phase (P2), the inductor (L) and the capacitor (C) are connected in series. The illumination sequence (Z2) comprises at least a third and at least a fourth phase. In the third phase (P3), the LED(s) (6), the inductor (L), and the capacitor (C) are connected in series. In the fourth phase (P4), the LED(s) and the inductor (L) are connected in series. In the charging sequence (Z1), the inductor (L) serves to transfer energy from the voltage source (B) to the capacitor (C).In the lighting sequence, the coil (L) is used for current regulation or control of the LEDs (6).

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The present application relates to a kind of intelligent ophthalmic phacoemulsification instrument, belong to medical instrument technical field, to solve the needle and bottle mouth sterile barrier of existing ophthalmic surgery liquid supply equipment in standby state are vulnerable to damage, and the switching delay caused by manual cap / cap is removed.The instrument includes body, solution suspension rod, Y-shaped infusion tube, replacement mechanism and handle.The replacement mechanism includes protection device with embedded rubber plug protection cylinder, and extension linkage structure for automatically opening bottle cap.In work, idle puncture needle is inserted into the rubber plug of protection cylinder and kept sterile wet state;When main infusion bottle is exhausted, motor and electric push rod linkage, drive replacement frame rotation and lifting, in the synchronous use of extension block automatic pull open the pop can of standby bottle, and the puncture needle pulled out from the protection plug is accurately inserted into new bottle.The present application not only realizes the automatic replacement of infusion bottle, ensures that perfusion liquid is in before entering the whole link sterile safety in eye.

A solubilizing composition for the poorly soluble drug rebamipide, its preparation method and application, and the solubilizing method, by combining rebamipide with a phosphorylated drug in a specific ratio, effectively improves the solubility of rebamipide in PBS. The solubilizing composition prepared by this invention significantly improves the bioavailability of rebamipide, providing a new approach for the development of oral and ophthalmic formulations of rebamipide.

The present application belongs to the technical field of biomedicine, and provides a pharmaceutical composition for inhibiting NFKBIZ gene expression, and a use. The present application designs a double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, the present application verifies a use of a pharmaceutical composition formed by the conjugation of the described nucleic acid molecules and targeting ligand molecules in ophthalmic diseases. The pharmaceutical composition can solve the problems with existing small molecule immunomodulatory drugs of low delivery efficiency and poor therapeutic effect, providing small nucleic acid drugs having tissue-targeted delivery functions, and has the advantages of long duration of efficacy and low side effects. In addition, the pharmaceutical composition has simple ingredients, is easy to synthesize, and has good prospects for translational applications.

The application discloses a protein zwitterionic polymer conjugate and a preparation method and application thereof. A multifunctional new medical biomaterial with mucosal adhesion, wetting, lubrication and microbial adhesion prevention is designed and synthesized, so that a new breakthrough is brought to the clinical demand of solving Sjogren's syndrome. In addition, the application has wide application prospects in the fields of oral lubrication, ophthalmic lubrication, joint repair and the like.